Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120678966> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W3120678966 endingPage "180" @default.
- W3120678966 startingPage "176" @default.
- W3120678966 abstract "Introduction: One of the major complications among COVID-19 patients include cardiac arrhythmias. Commonest arrhythmia is sinus tachycardia which is usually associated with palpitation causing discomfort to patients. In this study, we present a comparative study of use of Ivabradine vs. Carvedilol for sinus tachycardia in post-COVID-19 infected patients. Method: 50 consecutive recovered COVID-19 patients with sinus tachycardia were included in this open labelled RCT. 25 patients received Ivabradine and remaining 25 received Carvedilol. Single therapy non-responders were treated with Ivabradine with Atorvastatin. Results: The mean age of all patients is 48.8±7.66 years (Males 49.5 ± 7.21 years; Females 47.68 ± 8.23 years). The mean heart rate (MHR) of all patients is 125.52 ± 9.07/min (Males 125.67 ± 8.78/min; Females 125.26 ± 9.5/min). After five days of single drug therapy the mean drop in the heart rate was 35.04 ± 10.55/min (Males 34.41 ± 9.71/min; Females 36.05 ± 11.72/min), resulting in 27.88 ± 8.11% (Males 27.38 ± 7.56%; Females 28.69 ± 8.89%) reduction in MHR. Among the two groups, the Carvedilol group showed improvement of MHR in 14(56%) patients; whereas in Ivabradine group 18(72%) patients improved out of 25 patients each (p: 0.2385). In the Carvedilol group the MHR reduced from 128.6 ± 8.44 to 95.68 ± 10.63 (p < 0.001), which is statistically significant; similarly, the Ivabradine group showed a MHR from 122.44 ± 8.62 to 85.28 ± 10.52 (p < 0.001). The monotherapy therapy non-responders were treated with dual-therapy of (Ivabradine + Atorvastatin). Discussion: Ivabradine is more effective in controlling heart rate compared to Carvedilol. Also, Ivabradine group scores very well in ‘patient-satisfaction’ with regards to symptom (palpitation) relief. Conclusion: The COVID-19 sequelae of sinus tachycardia can be better controlled with Ivabradine when compared to Carvedilol." @default.
- W3120678966 created "2021-01-18" @default.
- W3120678966 creator A5002699213 @default.
- W3120678966 creator A5061586105 @default.
- W3120678966 date "2020-12-23" @default.
- W3120678966 modified "2023-09-27" @default.
- W3120678966 title "Ivabradine versus carvedilol in the management of palpitation with sinus tachycardia among recovered COVID-19 patients" @default.
- W3120678966 cites W2164013535 @default.
- W3120678966 cites W2540763217 @default.
- W3120678966 cites W3006485704 @default.
- W3120678966 cites W3011614543 @default.
- W3120678966 cites W3013224292 @default.
- W3120678966 cites W3014812319 @default.
- W3120678966 cites W3015520029 @default.
- W3120678966 cites W3015731395 @default.
- W3120678966 cites W3020512242 @default.
- W3120678966 cites W3045277594 @default.
- W3120678966 cites W3048853848 @default.
- W3120678966 cites W3165656738 @default.
- W3120678966 doi "https://doi.org/10.29328/journal.jccm.1001107" @default.
- W3120678966 hasPublicationYear "2020" @default.
- W3120678966 type Work @default.
- W3120678966 sameAs 3120678966 @default.
- W3120678966 citedByCount "3" @default.
- W3120678966 countsByYear W31206789662021 @default.
- W3120678966 countsByYear W31206789662022 @default.
- W3120678966 countsByYear W31206789662023 @default.
- W3120678966 crossrefType "journal-article" @default.
- W3120678966 hasAuthorship W3120678966A5002699213 @default.
- W3120678966 hasAuthorship W3120678966A5061586105 @default.
- W3120678966 hasBestOaLocation W31206789661 @default.
- W3120678966 hasConcept C126322002 @default.
- W3120678966 hasConcept C164705383 @default.
- W3120678966 hasConcept C2777482532 @default.
- W3120678966 hasConcept C2777953023 @default.
- W3120678966 hasConcept C2778198053 @default.
- W3120678966 hasConcept C2779167562 @default.
- W3120678966 hasConcept C2780144208 @default.
- W3120678966 hasConcept C2780283014 @default.
- W3120678966 hasConcept C2780591200 @default.
- W3120678966 hasConcept C42219234 @default.
- W3120678966 hasConcept C71924100 @default.
- W3120678966 hasConcept C84393581 @default.
- W3120678966 hasConceptScore W3120678966C126322002 @default.
- W3120678966 hasConceptScore W3120678966C164705383 @default.
- W3120678966 hasConceptScore W3120678966C2777482532 @default.
- W3120678966 hasConceptScore W3120678966C2777953023 @default.
- W3120678966 hasConceptScore W3120678966C2778198053 @default.
- W3120678966 hasConceptScore W3120678966C2779167562 @default.
- W3120678966 hasConceptScore W3120678966C2780144208 @default.
- W3120678966 hasConceptScore W3120678966C2780283014 @default.
- W3120678966 hasConceptScore W3120678966C2780591200 @default.
- W3120678966 hasConceptScore W3120678966C42219234 @default.
- W3120678966 hasConceptScore W3120678966C71924100 @default.
- W3120678966 hasConceptScore W3120678966C84393581 @default.
- W3120678966 hasIssue "3" @default.
- W3120678966 hasLocation W31206789661 @default.
- W3120678966 hasOpenAccess W3120678966 @default.
- W3120678966 hasPrimaryLocation W31206789661 @default.
- W3120678966 hasRelatedWork W1487656281 @default.
- W3120678966 hasRelatedWork W1975704641 @default.
- W3120678966 hasRelatedWork W2079812387 @default.
- W3120678966 hasRelatedWork W2116675910 @default.
- W3120678966 hasRelatedWork W2270618117 @default.
- W3120678966 hasRelatedWork W2610787159 @default.
- W3120678966 hasRelatedWork W2795216625 @default.
- W3120678966 hasRelatedWork W3120678966 @default.
- W3120678966 hasRelatedWork W4311589888 @default.
- W3120678966 hasRelatedWork W4319598235 @default.
- W3120678966 hasVolume "5" @default.
- W3120678966 isParatext "false" @default.
- W3120678966 isRetracted "false" @default.
- W3120678966 magId "3120678966" @default.
- W3120678966 workType "article" @default.